$VXRT The other company with a phase 2 Norovirus vax - Hillevax - is currently valued at a market cap of $488mln. Vaxart is valued at $422mln. Hillevax is worth more than Vaxart and yet Vaxart has a broader pipeline and platform busienss model/potential. Vaxart also has more cash and less debt. Many factors go into this though. But worth watching how the market values other vax makers - like Hillevax. finance.yahoo.com/quote/HLVX/